Gate Biosciences, a Brisbane, CA-based biotechnology company creating medicines called Molecular Gates, raised $60M in Series A funding.
The round was led by Versant Ventures and a16z Bio + Health, with participation from ARCH Venture Partners and GV.
The company intends to use the funds to expand operations and its development efforts.
Led by Jordi Mata-Fink, CEO, Gate Bioscience is a preclinical biotech company creating a new class of medicines called Molecular Gates. Its therapeutics are small molecules that aim to cure diseases by selectively eliminating harmful extracellular proteins at their origin: inside the cell. Every extracellular protein—of which there are more than 4,000—must pass through a single channel in the cell before it can be secreted into the body. Molecular Gates bind to this channel, setting up a “gate” that recognizes and blocks a specific, disease-causing protein from exiting. With nowhere to go, the protein is redirected to be degraded by the cell’s natural cleanup mechanism instead of being secreted. By eliminating the harmful protein at the source, Gate aims to eliminate the disease for patients.
Gate is led by:
- Jordi Mata-Fink, Ph.D., Co-Founder and Chief Executive Officer
- Pat Sharp, Ph.D., Scientific Co-Founder and Vice President of Discovery Science
- Raman Talwar, Co-Founder and Chief Technology Officer
- Brian Cathers, Ph.D., Chief Scientific Officer
FinSMEs
01/11/2023